Characteristics of CoolClot, the invented novel hemostatic agent

Background and ObjectivesUncontrolled bleeding is the first leading cause of preventable death in the battlefield and the second cause of mortality in civil accidents. Incompressible hemorrhage control is among the interventions that drastically increase the survival rate of the wounded individuals. Materials and MethodsThree healthy hybrid dogs were selected and after induction of anesthesia with Ether, either arterial puncture by a needle or arteriotomy was performed on both groin regions of the dogs. For control arteries, only a 4 min pressure using a sterile gauze was performed, while for the femoral arteries of the opposite side, Cool Clot hemostatic agent was topically used before the pressure. To assess the Coagulation Time (CT), blood samples were collected from 10 volunteer students. CT was measured by a chronometer according to standard Lee -White method.ResultsIn dog animal model, the Bleeding Time (BT) in control arteries (no hemostatic agent) was more than 15 minutes, while in case of the opposite sides which were treated with Cool Clot hemostatic agent, the BT was only up to 5 minutes. In the human phase of the study, the mean coagulation time in control blood samples was 253.4 ± 4.1 sec, while for blood samples treated with bentonite, zeolite and Cool Clot the mean times were 149.5 ± 50.0, 162.3 ± 74.5 and 143.4 ± 114.6 sec, respectively.ConclusionsThe results obtained in this study indicate the significant efficacy of Cool Clot in shortening the BT in dog model or CT in human blood samples.